Audio Medica - Medical Audio News Interviews & Podcasts » Medicine

Audio Journal of Medicine

admin — Tue, 20 May 2008 02:17:05 +0000

In this edition:

1. Training In Depression And Suicide: Need For Change?

Stan Kutcher, Dalhousie University, Nova Scotia

2. Suicide Paradox Explained: Australian National Strategy

Barry Nurcombe, Princess Margaret Hospital, Perth

3. Methylphenidate in the Real World

Manfred Döpfner, University of Cologne

4. Long Acting ADHD Treatments: Not All The Same

David Coghill, University of Dundee

Ralph Littlejohn interviewed some of the key speakers at the 2008 international conference on child mental health.

Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer

admin — Fri, 21 Mar 2008 22:37:17 +0000

Giorgio Scagliotti

Robert Pirker

GIORGIO SCAGLIOTTI, University of Turin
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.

New Targets Bring Promise For Lung Cancer Therapy

admin — Mon, 17 Mar 2008 23:18:55 +0000

Egbert Smit

EGBERT SMIT, Free University of Amsterdam
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein.

Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors

admin — Mon, 17 Mar 2008 23:17:04 +0000

Silvia Novello

SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

admin — Wed, 27 Feb 2008 17:47:03 +0000

Timothy Illidge

Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.

Meta-Analysis Proves Statins Help Patients With Diabetes

admin — Fri, 11 Jan 2008 10:34:49 +0000

Colin Baigent

REFERENCE: Lancet 371:117 January 11, 2008
COLIN BAIGENT, Oxford University
Statins were found to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.

Buy + Download Now This Interview

Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability

admin — Fri, 04 Jan 2008 12:39:28 +0000

Peter Tyrer

REFERENCE: Lancet 371:57 January 5, 2008
PETER TYRER, Imperial College, W6 8RP London
A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as “aggressive challenging behaviour” has shown that the anti-psychotic medicines gave no benefit. Peter Goodwin met up with Professor Peter Tyrer at London’s Imperial College to ask him about the study.

Buy + Download Now This Interview

New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

admin — Sun, 09 Dec 2007 16:41:12 +0000

Terry Gernsheimer

TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.

Large Risk Reduction For Rivaroxaban In Blood Clot Prevention

admin — Sun, 09 Dec 2007 15:03:23 +0000

Bengt Eriksson

REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.

Colistin Use Linked to Outbreak of Rare Hospital Infection

admin — Sun, 23 Sep 2007 16:17:52 +0000

Ramon Guevara

REFERENCE: Abstract K-1942, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
RAMON GUEVARA, Los Angeles County Department of Public Health
A report on a hospital outbreak involving a rare pathogen, which was presented at ICAAC, may have an important message for the whole field of infection control. Elizabethkingia Meningoseptica was found in a Los Angles hospital outbreak in 2006 and its emergence was linked to the use of colistin. So was this antibiotic selecting for the pathogen? Derek Thorne spoke with Ramon Guevara of Los Angeles County Department of Public Health.